The realization of particularly poor outcomes in MSS/BRAF-mutated CRC initially emerged from subgroup analyses in clinical trials, consistently indicating notably higher mortality in this subgroup compared to MSI-high or BRAF wild-type CRC [23,29]. This evidence concerns the gene BRAF and colorectal carcinoma.